New Antiepileptic Drugs

Sander JWAS Shorvon SD . Incidence and prevalence studies in epilepsy and their methodological problems: A review. J Neurol Neurosurg Psychiatry 1987; 50: 829–39.

Sander JWAS . Some aspects of prognosis in the epilepsies: A review. Epilepsia 1993; 34: 1007–16.

Patsalos PN Duncan JS . Antiepileptic drugs: A review of clinically significant drug interactions. Drug Safety 1993; 9: 158–84.

Patsalos PN . Phenobarbitone to gabapentin: A guide to 82 years of anti-epileptic drug pharmacokinetic interactions. Seizure 1994; 3: 163–70.

Brown GR Miyata M McCormack JP . Drug concentration monitoring. An approach to rational use. Clin Pharmacokinet 1993; 24: 187–94.

Halworth M Capps N. Therapeutic drug monitoring and clinical biochemistry. London: ACB Venture Publications, 1993.

Patsalos PN Sander JWAS Oxley J Lascelles PT . Immediate anticonvulsant drug monitoring in management of epilepsy. Lancet 1987; 2: 39.

Larkin JG Herrick AL McGuire GM Percy-Robb IW Brodie MJ . Antiepileptic drug monitoring at the epilepsy clinic: A prospective evaluation. Epilepsia 1991; 32: 89–95.

Patsalos PN Sander JWAS . Newer antiepileptic drugs. Towards an improved risk-benefit ratio. Drug Safety 1994; 11: 37–67.

Walker MC Patsalos PN . Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 1995; 67: 351–84.

Preece NE Jackson GD Houseman JA Duncan JS Williams SR . Nuclear magnetic resonance detection of increased GABA in vigabatrin-treated rats in vivo. Epilepsia 1994; 35: 431–6.

Patsalos PN Duncan JS . New antiepileptic drugs. A review of their current status and clinical potential. CNS Drugs 1994; 2: 40–77.

Patsalos PN Duncan JS . The pharmacology and pharmacokinetics of vigabatrin. Rev Contemp Pharmacother 1995; 6: 447–56.

Loscher W Fassbender CP Gram L Gramer M Horstermann D Zahner B Determination of GABA and vigabatrin in human plasma by a rapid and simple HPLC method: Correlation between clinical response to vigabatrin and increase in plasma GABA. Epilepsy Res 1993; 14: 245–55.

Ben-Menachem E Persson LI Schechter PJ Haegele KD Huebert N Hardenberg J The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 1989; 27: 79S–85S.

Arteaga R Herranz JL Valdizan EM Armijo JA . Gamma-vinyl GABA (vigabatrin): Relationship between dosage, plasma concentrations, platelet GABA-transaminase inhibition, and seizure reduction in epileptic children. Epilepsia 1992; 33: 923–31.

Gram L Lyon BB Dam M. Gamma-vinyl-GABA: A single blind trial in patients with epilepsy. Acta Neurol Scand 1983; 68: 34–9.

Armijo JA Cuadrado A Bravo J Arteaga R. Vigabatrin serum concentration to dosage ratio: Influence of age and associated antiepileptic drugs. Ther Drug Monit 1997; 19: 491–8.

Browne TR Mattson RH Penry JK Smith DB Treiman DN Wilder BJ Vigabatrin for refractory complex partial seizures: Multicenter single-blind study with long-term follow-up. Neurology 1987; 37: 184–9.

Tsanaclis LM Wicks J Williams J Richens A. Determination of vigabatrin in plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 1991; 13: 252–3.

Smithers JA Lang JF Okerholm RA . Quantitative analysis of vigabatrin in plasma and urine by reverse phase HPLC. J Chromatogr 1985; 341: 232–8.

Grove J Alken RG Schechter PJ . Assay of γ-vinyl-γ-aminobutyric acid (4-amino-hex-5-enoic acid) in plasma and urine by automated amino acid analysis. J Chromatogr 1984; 306: 383–7.

Juergens UH May TW Rambeck B. Simultaneous HPLC determination of vigabatrin and gabapentin in serum with automated pre-injection derivatization. J Liq Chrom Rel Technol 1996; 19: 1459–71.

Ratnaraj N Patsalos PN . A micromethod for the simultaneous determination of vigabatrin and gabapentin in serum by high performance liquid chromatography. Ther Drug Monit 1998; 20: 430–4.

Donaldson JA Glauser TA Olberding LS . Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox Gastaut syndrome). Epilepsia 1997; 38: 68–73.

Bartoli A Guerrini R Belmonte A Alessadri MG Gatti G Perucca E. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: A prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 1997; 19: 252–60.

Hussein Z Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: Retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997; 43: 457–64.

May TW Rambeck B Jurgens U. Serum concentrations of lamotrigine in epileptic patients: The influence of dose and comedication. Ther Drug Monit 1996; 18: 523–31.

Warner T Patsalos PN Prevett M Elyas AA Duncan JS . Lamotrigine-induced carbamazepine toxicity: An interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992; 11: 147–50.

Rambeck B Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433–43.

Cohen AF Ashby L Crowley D Lang G Peck AW . Lamotrigine (BW 430C), a new anticonvulsant: Effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol 1985; 20: 619–29.

Kilpatrick ES Forrest G Brodie MJ . Concentration-effect and concentration-toxicity relationships with lamotrigine: A prospective study. Epilepsia 1996; 37: 534–8.

Ramachandran S Underhill S Jones SR . Measurement of lamotrigine under conditions measuring phenobarbitone, phenytoin and carbamazepine using reversed-phase high-performance liquid chromatography at dual wavelengths. Ther Drug Monit 1994; 16. 75–82.

Fraser AD MacNeil W Isner AF Camfield PR . Lamotrigine analysis in serum by high-performance liquid chromatography. Ther Drug Monit 1995; 17: 174–8.

George S Wood AJ Braithwaite RA . Routine therapeutic monitoring of lamotrigine in epileptic patients using a simple and rapid high performance liquid chromatographic technique. Ann Clin Biochem 1995; 32: 584–8.

Forssblad E Eriksson AS Beck O. Liquid chromatographic determination of lamotrigine in pediatric samples. J Pharmaceut Biomed Anal 1996; 14: 755–8.

Lensmeyer GL Gidal BE Wiebe DA . Optimized high-performance liquid chromatographic determination of lamotrigine in serum with concomitant determination of phenytoin, carbamazepine, and carbamazepine epoxide. Ther Drug Monit 1997; 19: 292–300.

Hill DR Suman-Chauhan N Woodruff GN . Localisation of [³H] gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol 1993; 244: 303–9.

Petroff OAC Rothman DL Behar KL Lamoureaux D Mattson RH . The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996; 39: 95–9.

McLean MJ . Gabapentin. Epilepsia 1995; 36(Suppl 2): S57–S86.

Wilson EA Sills GJ Forrest G Brodie MJ . High dose gabapentin in refractory partial epilepsy: Clinical observations in 50 patients. Epilepsy Res 1998; 29: 161–6.

Tyndel F. Interaction of gabapentin with other antiepileptics. Lancet 1994; 343: 1363–4.

Beydoun A Fakhoury T Nasreddine W Abou-Khalil B. Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. Epilepsia 1998; 39: 188–93.

Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B, and the International Gabapentin Study Group. Gabapentin as add-on therapy in patients with partial seizures: A double-blind placebo-controlled study. Epilepsia 1994; 35: 795–801.

Sivenius J Kalviainen R Ylinen A Riekkinen P. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991; 32: 539–42.

Hengy H Kolle EU . Determination of gabapentin in plasma and urine by high-performance liquid chromatography and precolumn labelling for ultraviolet detection. J Chromatogr 1985; 341: 473–8.

Lensmeyer GL Kempf T Gidal BE Wirbe DA . Optimized method for determination of gabapentin in serum by high-performance liquid chromatography. Ther Drug Monit 1995; 17: 251–8.

Forrest G Sills GJ Leach JP Brodie MJ . Determination of gabapentin in plasma by high-performance liquid chromatography. J Chrom Biomed Appl 1996; 681: 421–5.

Langtry HD Gillis JC Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997; 54: 752–73.

Sachdeo RC Sachdeo SK Walker SA Kramer LD Nayak RK Doose DR . Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996; 37: 774–80.

Rosenfeld WE Liao S Kramer LD Anderson G Palmer M Levy RH Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997; 38: 324–33.

Oxis International, Inc. Innofluor® Topiramate Assay System reagent pack insert data sheet (number 7562/0597). Portland, Oregon, USA: Oxis International, Inc, 1997.

Holland ML Uetz JA Kung NG . Automated capillary gas chromatographic assay using flame ionization detection for the determination of topiramate in plasma. J Chrom Biomed Appl 1988; 433: 276–81.

Berry DJ Patsalos PN . Comparison of topiramate concentrations in plasma and serum. Epilepsia 1998; 39(Suppl 2): 67.

Marson AG Kadir ZA Chadwick DW . New antiepileptic drugs: A systematic review of their efficacy and tolerability. BMJ 1996; 313: 1169–74.

Walker MC Li LM Sander JWAS . Long term use of lamotrigine and vigabatrin in severe refractory epilepsy: Audit of outcome. BMJ 1996; 313: 1184–5.